Inoviv’s technology is based on using proteomics, the large-scale study of proteins in an individual, to match patients with drugs. The company is developing biomarker tests which can identify patients most likely to respond to the drug. Biomarker endpoints are also designed to demonstrate efficacy of treatment on an ongoing basis during the clinical trial.
Inoviv’s services include Patient Identification and Stratification, Companion Diagnostics and Treatment Efficacy Monitoring. The company measures more than 50 calibrating molecules per biofluid sample and analyzes 3000 biofluid/tissue samples per day. Their technology uses mass spectrometry-based targeted proteomics to test multiplexed protein, peptide, lipid and metabolite biomarker panels. Mass spectrometry measures the mass-to-charge ratio of molecules. Inoviv’s uses a triple quadrupole mass spectrometry system.
Inoviv pitched at Entrepreneur First’s 9th demo day in 2018.
Inoviv was founded.
As the triple quadrupole turns 40, mass spec gurus look back on what it's meant to chemistry | March 5, 2018 Issue - Vol. 96 Issue 10 | Chemical & Engineering News
Celia Henry Arnaud